Sanjay Patel
Allergy · Highland, INNPI 1962445528
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 372 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 28.9% of the total.
Across 372 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Genentech USA, Inc.$772
- CSL Behring$714
- GSK$476
- Novartis$394
- Covis Pharma GmbH$268
- plus $2K from 27 others
What the payments were for
- Consulting fees$140%
- Speaking & faculty fees$2003%
- Food & beverage$6,42196%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 97 | $1,930 |
| Genentech USA, Inc. | 37 | $772 |
| CSL Behring | 42 | $714 |
| GSK | 34 | $476 |
| Novartis | 25 | $394 |
| Covis Pharma GmbH | 18 | $268 |
| Aimmune Therapeutics, Inc. | 4 | $227 |
| Teva Pharmaceuticals USA, Inc. | 15 | $223 |
| Regeneron Healthcare Solutions, Inc. | 9 | $161 |
| Alk-abello, Inc | 10 | $144 |
| Amgen(2 entities) | 7 | $136 |
| Pfizer | 8 | $132 |
| Kaleo, Inc. | 8 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $123 |
| Biocryst US Sales Co., LLC | 8 | $119 |
| Sanofi | 5 | $94 |
| Boehringer Ingelheim | 5 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $91 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $88 |
| Grifols USA, LLC | 3 | $61 |
| Shire North American Group Inc | 3 | $50 |
| Pharming Healthcare, Inc. | 2 | $47 |
| Merck | 2 | $29 |
| USWM, LLC | 2 | $29 |
| Optinose US, Inc. | 2 | $25 |
| Bio Products Laboratory USA, Inc. | 2 | $19 |
| Tersera Therapeutics LLC | 1 | $16 |
| Octapharma USA, Inc. | 1 | $16 |
| Ionis Pharmaceuticals, Inc. | 1 | $15 |
| Biocryst Pharmaceuticals, Inc. | 1 | $14 |
| ADMA Biomanufacturing LLC | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Kedrion Biopharma, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 31 | $96,433 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 36 | $74,287 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 24 | $50,090 |
| Dupixent SyringeDupilumab | 11 | $41,162 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $14,622 |
| Arnuity ElliptaFluticasone Furoate | 21 | $6,582 |
| Epinephrine | 19 | $2,970 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $1,220 |
| Fluticasone Propionate | 63 | $986 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $928 |
| Hydroxyzine Hcl | 46 | $842 |
| Ipratropium Bromide | 31 | $710 |
| Montelukast Sodium | 114 | $692 |
| Azelastine Hcl | 21 | $605 |
| Famotidine | 17 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Gammagard Liquid | $123 | $124,37760 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $476 | $21,20448 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $2,97019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other allergy in Highland
- Carol FossoIndianapolis$5K
- Lauren RiggValparaiso$4K
- Mark HolbreichIndianapolis$2K
- Nagarjuna PonugotiTerre Haute$2K
- Damir MatesicKokomo$2K
- Sai KarlapudiMuncie$1K
- Jay ProchnauLafayette$662
- Naresh PatelFort Wayne$404
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.